EDX Medical to Market Pioneering Cancer Drugs Response Assay in UK and Nordics
EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces today it has signed an exclusive distribution agreement with Curesponse Ltd, to market the cResponse™ cancer assay in the UK, Sweden, Finland, Norway and Denmark.
cResponse™ is a groundbreaking platform that biologically assesses how an individual patient’s living tumour tissue responds to selected medicines, identifying the most effective treatment options. It is the only clinical-grade technology providing biological response data for chemotherapy, targeted biologics, and immunotherapy drugs. This platform helps clinicians rapidly pinpoint optimal treatments, potentially saving lives, reducing treatment costs, and accelerating the discovery and development cycles for pharmaceutical companies seeking new cancer drugs.
The cResponse™ platform generates a report ranking selected cancer drugs based on their predicted effect on an individual patient’s tumour, demonstrating over 90% accuracy in clinical trials. The test can be augmented with rapid genomic sequencing to identify additional drug candidates for functional analysis. The entire process is powered by proprietary technologies and advanced AI algorithms. The platform technology has been refined and calibrated using thousands of cancer tissues, demonstrating its clinical utility and effectiveness through hundreds of cases in Israel and the UK. The cResponse™ test is performed at a United Kingdom Accreditation Service (UKAS) accredited lab in London and has also earned a CE mark for Europe, underscoring its regulatory approval and readiness for clinical use.
EDX Medical will initiate commercial activities to support the clinical use of the cResponse™ assay in the UK and Nordics with immediate effect and will explore broadening the agreement with Curesponse in due course.
Professor Sir Chris Evans, OBE, founder of EDX Medical plc, commented: “We are delighted to be increasing accessibility to this genuinely innovative and pioneering test which potentially offers tremendous benefit to those treating cancer and their patients. This product is an excellent addition to our rapidly growing portfolio of class-leading diagnostic solutions.”
Dr Mike Hudson, CEO, EDX Medical plc, said: “We are very pleased to have been selected by Curesponse as their partner, and to be able to make their breakthrough assay available for our clients in the UK and Nordics. We consider cResponse™ to be an outstanding innovation in the fast-moving clinical cancer diagnostic landscape.”
Guy Neev, CEO of Curesponse Ltd, commented: “We are thrilled to partner with EDX Medical Group to bring our cResponse™ platform to patients and clinicians in the UK and Nordic countries. Our mission at Curesponse is to make this technology available to cancer patients to optimize treatment outcomes and save lives. This collaboration is a significant step toward achieving that goal. We look forward to working closely with the EDX Medical team to ensure the successful adoption and implementation of this groundbreaking decision support tool.”
About EDX Medical Groupplc
The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX). www.edxmedical.com
About Curesponse Ltd.Curesponse is a pioneering leader in precision oncology. www.curesponse.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626860842/en/
Contacts
EDX Medical plc
Dr Mike Hudson (Chief Executive Officer)
+44 (0)7812 345 301
Media House International
Ramsay Smith
+44 (0)7788 414856
ramsay@mediahouse.co.uk
Gary McQueen
+ 44 (0)7834 694609
gary@mediahouse.co.uk
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses28.6.2024 17:30:00 CEST | Press release
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announces new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY® (fremanezumab) that may challenge the rationale for treatment pauses with calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) mandated or recommended by some reimbursement authorities after one year of continuous use. The sub-analysis from the PEARL real world data explored the impact of fremanezumab treatment cessation and reinitiation on monthly migraine days (MMD) in adult patients with episodic or chronic migraine. The data1 show that pausing treatment of fremanezumab, a CGRP-pathway mAb, may result in a potential rise in monthly migraine days (MMD) following treatment cessation and reduced effectiveness upon reinitiation compared to the first treatment cycle, adding to the burden of the individual living with migraine: Over 40% of patients experienced a rapid worsening of their migraine (>=50% increase in
Yard Force Introduces the 21W Portable Solar Charger with Dual USB Ports and 13000 mAh Built-in Battery28.6.2024 08:07:00 CEST | Press release
Yard Force is excited to announce the launch of the 21W Portable Solar Charger, a revolutionary device designed to provide reliable and efficient power for all your USB devices, whether you are indoors or outdoors. This innovative product combines the functionality of a powerful 13000 mAh power bank with high-efficiency solar panels, offering a seamless and eco-friendly solution for all your charging needs. The Yard Force 21W Portable Solar Charger is now available for purchase on Amazon.de here. Key Features of the Yard Force 21W Portable Solar Charger: Evolutionary Dual Functionality: The Yard Force 21W combines a robust 13000 mAh power bank with efficient solar cells to ensure continuous power supply. Whether indoors or outdoors, you can rely on this device for all your power needs, eliminating the hassle of carrying multiple gadgets. Unlimited Solar Energy: Equipped with industry-leading solar cells, this charger converts up to 24% of sunlight into energy, ensuring your power bank
AQEMIA Achieves Research Milestone Against Undruggable Target in Immuno-Oncology with Servier28.6.2024 07:30:00 CEST | Press release
AQEMIA, a leading company in generative-AI-driven drug discovery, announces the achievement of a research milestone in its collaboration with Servier, an international independent pharmaceutical company, to address an undruggable target in immuno-oncology. Based on AQEMIA ‘s quantum and statistical physics-based calculations, and within the span of a few months, a series of molecules experimentally active on an undruggable target in immuno-oncology have been successfully identified. This milestone triggers an undisclosed payment to AQEMIA. "Our teams are very proud of this achievement that demonstrates the power of AQEMIA's cutting-edge generative AI and deep physics in creating novel, patentable molecules to meet therapeutic needs that are still immense, particularly in the field of immuno-oncology. Within the framework of our collaboration with Servier, we have reached the stage where a series of molecules are subsequently proven impactful in vitro and in vivo assays. " said Maximili
Yard Force Launches the LX PS300 Portable Power Station - Your Ultimate Mobile Power Solution28.6.2024 06:12:00 CEST | Press release
Yard Force is excited to announce the launch of the LX PS300 Portable Power Station, a versatile and powerful battery backup solution designed for a variety of applications, from camping and outdoor activities to emergency power supply. With a battery capacity of 296Wh and peak output of 600W, the LX PS300 provides reliable and efficient power for all your electronic devices. The Yard Force LX PS300 Portable Power Station is now available for purchase on Amazon.de here. Key Features of the Yard Force LX PS300 Portable Power Station: Mobile Power Supply: The LX PS300 is the ideal portable power station for camping, RV trips, outdoor activities, garden sheds, picnics, festivals, or as an emergency power supply. It offers a battery capacity of 296Wh (600W peak) and is suitable for use with electronic devices such as smartphones, tablets, and more. Fast Recharge Time: Compatible with separately available solar panels (LX SPP10/100W and LX SPP20/200W), the LX PS300 can be fully recharged in
Yard Force Introduces the 100W Portable Solar Panel LX SPP10 - Your Ideal Solar Charging Solution28.6.2024 06:00:00 CEST | Press release
Yard Force is proud to unveil the 100W Portable Solar Panel LX SPP10, a highly efficient and versatile solar charger designed to provide optimal power supply in conjunction with Yard Force Power Stations. Perfect for outdoor activities and emergency power needs, the LX SPP10 ensures reliable and eco-friendly energy wherever you go. The Yard Force 100W Portable Solar Panel is now available for purchase on Amazon.de here. Key Features of the Yard Force 100W Portable Solar Panel LX SPP10: Mobile Power Supply: Specifically designed to maximize performance when paired with Yard Force Power Stations, the 100W solar panel boasts an impressive efficiency rate of 23.5% and 95% transparency for efficient conversion of solar energy into electrical power. Waterproof Design: With its seamless construction, the Yard Force 100W Solar Panel is waterproof, making it perfect for all outdoor activities. Whether camping, hiking, or in an emergency situation, this solar panel ensures a continuous power sup
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom